Caxton Associates LP
- SEC CIK
- 0000872573
- Latest filing
- Feb 14, 2025
CPRX holding history
Catalyst Pharmaceuticals, Inc. in every 13F filed by Caxton Associates LP, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CPRX overviewAll 13F holders of CPRXFull Q4 2024 holdings
- Shares (Q4 2024)
- 0
- Sold out in Q4 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 7
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2024 | 0 | $0 | 0.0% | −20,762−100.0% | Sold out | Holders |
| Q3 2024 | 20,762 | $412.7K | <0.1% | +20,762 | New | Holders |
| Q3 2022 | 0 | $0 | 0.0% | −32,338−100.0% | Sold out | Holders |
| Q2 2022 | 32,338 | $227.0K | <0.1% | −92,264−74.0% | Reduced | Holders |
| Q1 2022 | 124,602 | $1.03M | 0.1% | +83,992+206.8% | Added | Holders |
| Q4 2021 | 40,610 | $275.0K | <0.1% | 00.0% | Unchanged | Holders |
| Q3 2021 | 40,610 | $215.0K | <0.1% | −2,413−5.6% | Reduced | Holders |
| Q2 2021 | 43,023 | $247.0K | <0.1% | +18,431+74.9% | Added | Holders |
| Q1 2021 | 24,592 | $113.0K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.